THE EFFECTS OF DIET THERAPY ON CLINICAL AND BIOCHEMICAL PARAMETERS AND BODY COMPOSITION IN OVERWEIGHT

Background:   Only  medical   nutrition   therapy and physical activity can be used for treatment of the group  2 (p > 0.05). The fat mass in children of the group  1 decreased from 44.4% [39.1; 48.3] to Department of Pediatric Gastroenterology, Hepatology, and Nutrition1; Assistant, Chair of Dietetics and2obesity in children. In many cases, it is reasonable to  start  treatment in a hospital. Aim: To assess changes  of clinical and  biochemical  parameters and body composition with diet therapy in overweight  and  obese  children  in an  in-patient department. Materials and methods: We examined 537 children with obesity aged 13 years [11;  14] (group  1) and  104  overweight   children aged  13 [12; 14] years (group  2). Anthropometric parameters,   body   composition    by   means   ofbioimpedance  measurement,  clinical  chemistry 43.1% [37.9; 47.7] (p < 0.001), in group 2, from 33.8% [31.1; 38.5] to 32.6% [30; 36.7] (p = 0.017). The lean mass  decreased in 86.2 and  93.7% of patients, respectively.  There  were  significant  reductions on  the   levels  of  serum   total   cholesterol,  low density lipoproteins, triglycerides, high density lipoproteins  and  increase  in uric acid, compared to  their  respective  baseline  values. Conclusion: During  the  in-hospital  treatment period  obese children  show  improvements  of nutritive  status, Nutrition, Postgraduate Training FacultyPavlyuchkova Mariya S. – PhD, Dietologist1parameters of lipid and carbohydrate metabolism significant   reduction   of   fat   body   mass   with                were  assessed   at  baseline   and  at  the   end   of treatment. Duration of hospital stay was 14 days. The  children   were  on  a  diet  with  a  reduced caloric,  fat  and  carbohydrate  content.  Results: The bodymass  decreased by 5.7% [4.5; 6.9] from baseline  in the  group  1 and  by 5.3% [3.8; 7.5] in concomitant decrease  of lean mass due to a rapidbodyweight reduction

THE STUDY THE EFFICACY AND SAFETY OF ANTIMICROBIAL AGENTS

Abstract:Effective treatment of patients with infectious and inflammatory diseases of the skin and mucous membranes often involves the use of antimicrobial agents.The purpose of the study was an in vitro estimation of cytotoxicity and the efficiency of national resources for local use: gel with bacteriophages («Otofag», «Fagogin», «Fagoderm», «Fagodent») and antiseptic — «Сhlorhexidine» and «Miramistin».Materials and Methods. To study the effectiveness of antimicrobial agents they used to provide crop strains of Staphylococcus aureus and Streptococcus pyogenes as one of the most common representatives of pathogens. The study of cell viability and cytotoxicity antimicrobials performed on cell lines KB — epidermoid carcinoma of the oral cavity of a human. For this purpose we use mikrotetrazoly test, which is widely used in the assessment of the effects on the cells of toxins, pharmaceuticals, adverse environmental factors, allowing to evaluate the toxicity of investigational drugs in vitro.The results showed that the efficacy against pathogens Staphylococcus aureus and Streptococcus pyogenes, has even a 10‑fold dilution of «Сhlorhexidine» 0.05% and gels with bacteriophages. Antiseptic «Miramistin» is effective only on the initial concentration. The study of cytotoxicity showed that the processing of epidermoid carcinoma cells with «Chlorhexidine» and «Мiramistin» invokes the irreversible reactions, while the composition processing of gels based on bacteriophages not further affect cell viability.Conclusions The results of the experiment confirmed the significant toxicity of tools such as «Сhlorhexidine» and «Miramistin» in proposed concentrations in the pharmacy network. Despite the high efficiency of these vehicles with regard to the studied pathogens, their long-term use in treatment of inflammatory diseases of the skin and mucous membranes can cause a slowing of repair processes. Gel means with bacteriophages «Fagodent» «Otofag» «Fagogin» and «Fagoderm» are highly effective and have no toxic effects on the cells. In this regard, they can be an effective and safe alternative to the popular antiseptic

Continuous glucose monitoring in children with glycogenosis

Rationale: Glycogen storage diseases (GSD, glycogenosis) are a group of hereditary disorders of carbohydrate metabolism that is characterized by excess glycogen accumulation in various organs and tissues due to deficiency or absence of glycogen-splitting enzymes. GSD diagnostics requires an assessment of the patient's health status, severity and frequency of hypoglycemias, as well as the choice of a strategy for nutritional support to prevent hypoglycemia.Aim: To assess efficacy of continuous glucose monitoring (CGM) as a  new method to diagnose hypoglycemia in children with hepatic types of GSD and the role of this assessment method in personalization of nutritional regimen in these disorders.Materials and methods: The study included 51 child with confirmed diagnosis of GSD at the age of 6.9 ± 0.7  years, of them 36  boys and 15  girls. Thirty three percent of patients had GSD type I, 22% – type III, 45% – types VI and IX. All patients had their glycemic levels measured as glycemic profiles and oral glucose tolerance test (OGTT), as well as by means of real-time CGM. The results were analyzed both in the whole group of patients and in the groups with various GSD types.Results: Measurement of glycemic profiles in children with GSD at daytime did not detect any significant abnormalities. During OGTT, more rapid decline of glucose levels was seen in younger kids and in patients with GSD type I; however, the differences were not statistically significant (11  patients (65%  of cases) had the lowest glucose levels at 180  minutes of the test: 3.1 ± 0.3 mmol/L, p > 0.05). Fasting hypoglycemia in the OGTT was found in 4  (24%) children with GSD type I  and in 3  (13%) children with GSD types VI and IX. Hypoglycemia at the end of the test was seen in 13 (76%) patients with GSD type I, in 3 (27%) with type III, and in 12 (55%) with types VI and IX. CGM showed hyperglycemia (10.2 ± 0.3 mmol/L) for 1 to 1.5 hours after a meal. Hypoglycemic episodes were registered at night time in 48 (94.1%) of children indicating the need for additional night feeding. Maximal total duration of low glucose levels was found in type  I  of the disease (10.2 ± 2.4  hours). Analysis of CGM results depending on GSD type showed that despite comparable glucose levels, more significant abnormalities are found in GSD type I (the proportion of hyperglycemic periods was 10.2 ± 2.3%, their duration 6.9 ± 1.8  hours; the proportion of hypoglycemic periods was 13.5 ± 2.6%, their duration 10.2 ± 2.4 hours, p < 0.05).Conclusion: The results obtained indicate the necessity to use CGM in all GSD patients to diagnose and prevent hypoglycemia that would be the basis to elaborate individual nutritional recommendations

The temporally controlled expression of Drongo, the fruit fly homolog of AGFG1, is achieved in female germline cells via P-bodies and its localization requires functional Rab11

<p>To achieve proper RNA transport and localization, RNA viruses exploit cellular vesicular trafficking pathways. AGFG1, a host protein essential for HIV-1 and Influenza A replication, has been shown to mediate release of intron-containing viral RNAs from the perinuclear region. It is still unknown what its precise role in this release is, or whether AGFG1 also participates in cytoplasmic transport. We report for the first time the expression patterns during oogenesis for Drongo, the fruit fly homolog of AGFG1. We find that temporally controlled Drongo expression is achieved by translational repression of <i>drongo</i> mRNA within P-bodies. Here we show a first link between the recycling endosome pathway and Drongo, and find that proper Drongo localization at the oocyte's cortex during mid-oogenesis requires functional Rab11.</p

Development and Validation of Pomalidomide Determination in Human Plasma by HPLC-MS/MS Method

Introduction. B-cell malignancies of the plasma cell leads to the second most spread hematological malignancy disease, called multiple myeloma. Pomalidomide is used in case of previous multiple myeloma ineffective treatment. Pomalidomide is a thalidomide synthetic derived, approved as immunomodulatory drug by the Food and Drug Administration (FDA). Nowadays, detection of pomalidomide in blood plasma by high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) is not spread. Moreover, the detection and the experimental setting accumulated data are varying greatly. This investigation provides development and validation of pomalidomide aiming to determine human blood plasma by HPLC-MS/MS method. The samples were processed by methanol protein precipitation.Aim. The aim of this study is to develop a method for the pomalidomide in human plasma by HPLC-MS/MS for pharmacokinetic studies.Materials and methods. Determination of pomalidomide in plasma by HPLC-MS/MS. The samples were processed by methanol protein precipitation.Results and discussion. This method was validated by next parameters: selectivity, matrix effect, calibration curve, accuracy, precision, spike recovery, lower limit of quantification, detection limit, carry-over and stability.Conclusion. The method of the determination of pomalidomide in human plasma was developed and validated by HPLC-MS/MS. The linearity in plasma sample was achieved in the concentration range of 1,00 – 500,00 ng/ml. Method could be applied to pomalidomide determination in plasma for PK and BE studies

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers

Introduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors. Phase I clinical trial was performed to assess pharmacokinetics (PK) and immunogenicity of bevacizumab drugs. For this study 80 healthy male volunteers were recruited and randomized to either Avastin or RPH-001 group.Aim. To assess and compare pharmacokinetics and immunogenicity (safety) following single intravenous administration of Avastin® (manufactured by F. Hoffmann-La Roche Ltd., Switzerland) and bevacizumab biosimilar RPH-001 (manufactured by R-Pharm Group, Russia).Materials and methods. Bevacizumab quantitation and quasi-quantitative anti-bevacizumab antibodies detection in human blood serum were carried out using photometric ELISA. Two different methods were successfully validated.Results and discussion. Bevacizumab quantitation method was validated for selectivity and specificity, calibration curve, sensitivity, accuracy and precision, minimal required dilution, dilution linearity and stability. The anti-bevacizumab antibodies detection method was validated for cut-point (with normalization factor calculation), selectivity, sensitivity, precision, drug tolerance, dilution linearity, matrix effect (in case of serum hemolysis), and stability. The validated methods were successfully applied to pharmacokinetic and immunogenicity assessment of bevacizumab drugs.Conclusion. The results of the PK-study showed that test and reference bevacizumab drugs were equivalent. Immunogenicity study did not show any evidence of anti-bevacizumab antibodies in blood serum samples